# Bryan Wood

> Bryan Wood is a Series C investor at +ND Capital backing Medical. See 1 investment, round sizes, portfolio and contact details. Updated Nov 2026.

- Type: Angel Investor
- Fund: [+ND Capital](https://shizune.co/investors/profile/nd-capital)
- Location: Geneva, Switzerland
- Total investments: 1
- Last investment: Jun 2010
- Lead investor: 0%
- Last updated: Nov 2026
- LinkedIn: https://www.linkedin.com/in/bryan-wood-3356a021

Bryan Wood is a member of the CyberCity 3D Board of Directors. He is Founder and Managing General Partner at Geneva, Switzerland-based Alta Berkley, which handles capital funds investing in early stage communications, information technology, and media and health care in Western Europe. Mr. Wood is experienced in all areas of business includingfundraising, investor relations, law, taxes, and administration. He contributes added expertise in management, having served on the Board of Directors of 50 European, American, and Israeli companies. He has a Masters in Business Administration degree with an emphasis on Finance from Harvard University. He won his BSc in Industrial Engineering degree from Virginia Polytechnic Institute.

## Contacts

5 contacts available for Bryan Wood: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/bryan-wood-2?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |
| Clinical Trials | 1 | 100% |
| Information Technology | 1 | 100% |

## Investments

| Company | Description | Round size | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| BIND Therapeutics | They are a clinical-stage nanomedicine platform company developing Accurins™, our novel targeted and programmable therapeutics. Accurins are designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease to enhance efficacy while minimizing adverseeffects on healthy tissues. Our strategy is to leverage our medicinal nanoengineering platform to develop our own pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. Our lead drug candidate, BIND-014, is in Phase 2 clinical trials for non-small cell lung cancer (NSCLC) and metastatic castrate-resistant prostate cancer (mCRPC). To date in 2013, we have announced collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines. | $12.4M | Series C | Jun 29, 2010 | http://bindtherapeutics.com |

1 of 1 investments shown.

## Co-investors
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [Endeavour Vision](https://shizune.co/investors/profile/endeavour-vision) — VC Fund, 1 deal together
- [NanoDimension](https://shizune.co/investors/profile/nanodimension) — VC Fund, 1 deal together

## About +ND Capital

VC Fund · San Mateo, United States

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.

5 contacts available at +ND Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Eric Moessinger | Partner | https://shizune.co/investors/profile/eric-moessinger |
| Jonathan Nicholson | Director | https://shizune.co/investors/profile/jonathan-nicholson |
| Kirill Kuzmichev | Principal | https://shizune.co/investors/profile/kirill-kuzmichev |
| Louis-Philippe Lalonde | Entrepreneur-In-Residence | https://shizune.co/investors/profile/louis-philippe-lalonde-fab9 |
| Richard Coles | Director | https://shizune.co/investors/profile/richard-coles |

## Similar investors

### Similar stage
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund

## FAQ

### What does Bryan Wood invest in?

Bryan Wood invests primarily in Medical, Health Care and Biotechnology startups, most often at Series C stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Bryan Wood?

Public channels for Bryan Wood include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Bryan Wood last invest?

The most recent investment recorded for Bryan Wood closed in Jun 2010. Shizune tracks 1 investment in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co